BACKGROUND: Interleukin-17 (IL-17) has been demonstrated to promote formation and growth of hormone-naïve prostate adenocarcinoma in mice. IL-17's role in development of castration-resistant prostate cancer is unknown. In the present study, we investigated IL-17's role in castration-resistant prostate cancer in a mouse model. METHODS: IL-17 receptor C (IL-17RC) deficient mice were interbred with Pten conditional mutant mice to produce RC(+) mice that maintained IL-17RC expression and RC(-) mice that were IL-17RC deficient. Male RC(+) and RC(-) mice were Pten-null and were castrated at 16 weeks of age when invasive prostate cancer had already formed. At 30 weeks of age, all male mice were analyzed for the prostate phenotypes. RESULTS: RC(-) mice displayed prostates that were smaller than RC(+) mice. Approximately 23% of prostatic glands in RC(-) mice, in contrast to 65% of prostatic glands in RC(+) mice, developed invasive adenocarcinomas. Compared to castrate RC(+) mice, castrate RC(-) mouse prostate had lower rates of cellular proliferation and higher rates of apoptosis as well as lower levels of MMP7, YBX1, MTA1, and UBE2C proteins. In addition, castrate RC(-) mouse prostate had less angiogenesis, which was associated with decreased levels of COX-2 and VEGF. Moreover, castrate RC(-) mouse prostate had fewer inflammatory cells including lymphocytes, myeloid-derived suppressor cells, and macrophages. CONCLUSIONS: Taken together, our findings suggest that IL-17 promotes development of invasive prostate adenocarcinomas under castrate conditions, potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.
BACKGROUND:Interleukin-17 (IL-17) has been demonstrated to promote formation and growth of hormone-naïve prostate adenocarcinoma in mice. IL-17's role in development of castration-resistant prostate cancer is unknown. In the present study, we investigated IL-17's role in castration-resistant prostate cancer in a mouse model. METHODS:IL-17 receptor C (IL-17RC) deficient mice were interbred with Pten conditional mutant mice to produce RC(+) mice that maintained IL-17RC expression and RC(-) mice that were IL-17RC deficient. Male RC(+) and RC(-) mice were Pten-null and were castrated at 16 weeks of age when invasive prostate cancer had already formed. At 30 weeks of age, all male mice were analyzed for the prostate phenotypes. RESULTS: RC(-) mice displayed prostates that were smaller than RC(+) mice. Approximately 23% of prostatic glands in RC(-) mice, in contrast to 65% of prostatic glands in RC(+) mice, developed invasive adenocarcinomas. Compared to castrate RC(+) mice, castrate RC(-) mouse prostate had lower rates of cellular proliferation and higher rates of apoptosis as well as lower levels of MMP7, YBX1, MTA1, and UBE2C proteins. In addition, castrate RC(-) mouse prostate had less angiogenesis, which was associated with decreased levels of COX-2 and VEGF. Moreover, castrate RC(-) mouse prostate had fewer inflammatory cells including lymphocytes, myeloid-derived suppressor cells, and macrophages. CONCLUSIONS: Taken together, our findings suggest that IL-17 promotes development of invasive prostate adenocarcinomas under castrate conditions, potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.
Authors: Laura V July; Majid Akbari; Tobias Zellweger; Edward C Jones; S Larry Goldenberg; Martin E Gleave Journal: Prostate Date: 2002-02-15 Impact factor: 4.104
Authors: J R Graff; B W Konicek; A M McNulty; Z Wang; K Houck; S Allen; J D Paul; A Hbaiu; R G Goode; G E Sandusky; R L Vessella; B L Neubauer Journal: J Biol Chem Date: 2000-08-11 Impact factor: 5.157
Authors: Muneo Numasaki; Jun-ichi Fukushi; Mayumi Ono; Satwant K Narula; Paul J Zavodny; Toshio Kudo; Paul D Robbins; Hideaki Tahara; Michael T Lotze Journal: Blood Date: 2002-10-31 Impact factor: 22.113
Authors: M Mercader; B K Bodner; M T Moser; P S Kwon; E S Park; R G Manecke; T M Ellis; E M Wojcik; D Yang; R C Flanigan; W B Waters; W M Kast; E D Kwon Journal: Proc Natl Acad Sci U S A Date: 2001-12-04 Impact factor: 11.205
Authors: Cory Abate-Shen; Whitney A Banach-Petrosky; Xiaohui Sun; Kyriakos D Economides; Nishita Desai; Jeffery P Gregg; Alexander D Borowsky; Robert D Cardiff; Michael M Shen Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701
Authors: Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: Sen Liu; Fengli Liu; Bing Zhang; Peng Yan; Brian G Rowan; Asim B Abdel-Mageed; Chad Steele; S Michal Jazwinski; Krzysztof Moroz; Elizabeth B Norton; Alun Wang; Leann Myers; Oliver Sartor; Qiuyang Zhang Journal: Prostate Date: 2020-05-01 Impact factor: 4.104
Authors: Qiuyang Zhang; Sen Liu; Dongxia Ge; David M Cunningham; Feng Huang; Lin Ma; Thomas P Burris; Zongbing You Journal: Prostate Date: 2017-02-27 Impact factor: 4.104
Authors: David Cunningham; Qiuyang Zhang; Sen Liu; Keshab R Parajuli; Qiang Nie; Lin Ma; Allen Zhang; Zhenbang Chen; Zongbing You Journal: Am J Clin Exp Urol Date: 2018-06-15